Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors

Abstract We have developed a high-throughput drug discovery platform, measuring fluorescence resonance energy transfer (FRET) with fluorescent alpha-synuclein (αSN) biosensors, to detect spontaneous pre-fibrillar oligomers in living cells. Our two αSN FRET biosensors provide complementary insight in...

Full description

Bibliographic Details
Main Authors: Anthony R. Braun, Elly E. Liao, Mian Horvath, Prakriti Kalra, Karen Acosta, Malaney C. Young, Noah Nathan Kochen, Chih Hung Lo, Roland Brown, Michael D. Evans, William C. K. Pomerantz, Elizabeth Rhoades, Kelvin Luk, Razvan L. Cornea, David D. Thomas, Jonathan N. Sachs
Format: Article
Language:English
Published: Nature Publishing Group 2021-06-01
Series:npj Parkinson's Disease
Online Access:https://doi.org/10.1038/s41531-021-00195-6
id doaj-ee6b8563f73c49f68804418a48d07270
record_format Article
spelling doaj-ee6b8563f73c49f68804418a48d072702021-07-04T11:33:55ZengNature Publishing Groupnpj Parkinson's Disease2373-80572021-06-017111710.1038/s41531-021-00195-6Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensorsAnthony R. Braun0Elly E. Liao1Mian Horvath2Prakriti Kalra3Karen Acosta4Malaney C. Young5Noah Nathan Kochen6Chih Hung Lo7Roland Brown8Michael D. Evans9William C. K. Pomerantz10Elizabeth Rhoades11Kelvin Luk12Razvan L. Cornea13David D. Thomas14Jonathan N. Sachs15Department of Biomedical Engineering, University of MinnesotaDepartment of Biomedical Engineering, University of MinnesotaDepartment of Pathology and Laboratory Medicine, University of PennsylvaniaDepartment of Chemistry, University of MinnesotaBiochemistry & Molecular Biophysics Graduate Group, University of PennsylvaniaDepartment of Biomedical Engineering, University of MinnesotaDepartment of Biomedical Engineering, University of MinnesotaDepartment of Biomedical Engineering, University of MinnesotaClinical and Translational Science Institute, University of MinnesotaClinical and Translational Science Institute, University of MinnesotaDepartment of Chemistry, University of MinnesotaBiochemistry & Molecular Biophysics Graduate Group, University of PennsylvaniaDepartment of Pathology and Laboratory Medicine, University of PennsylvaniaDepartment of Biochemistry, Molecular Biology and Biophysics, University of MinnesotaDepartment of Biochemistry, Molecular Biology and Biophysics, University of MinnesotaDepartment of Biomedical Engineering, University of MinnesotaAbstract We have developed a high-throughput drug discovery platform, measuring fluorescence resonance energy transfer (FRET) with fluorescent alpha-synuclein (αSN) biosensors, to detect spontaneous pre-fibrillar oligomers in living cells. Our two αSN FRET biosensors provide complementary insight into αSN oligomerization and conformation in order to improve the success of drug discovery campaigns for the treatment of Parkinson’s disease. We measure FRET by fluorescence lifetime, rather than traditional fluorescence intensity, providing a structural readout with greater resolution and precision. This facilitates identification of compounds that cause subtle but significant conformational changes in the ensemble of oligomeric states that are easily missed using intensity-based FRET. We screened a 1280-compound small-molecule library and identified 21 compounds that changed the lifetime by >5 SD. Two of these compounds have nanomolar potency in protecting SH-SY5Y cells from αSN-induced death, providing a nearly tenfold improvement over known inhibitors. We tested the efficacy of several compounds in a primary mouse neuron assay of αSN pathology (phosphorylation of mouse αSN pre-formed fibrils) and show rescue of pathology for two of them. These hits were further characterized with biophysical and biochemical assays to explore potential mechanisms of action. In vitro αSN oligomerization, single-molecule FRET, and protein-observed fluorine NMR experiments demonstrate that these compounds modulate αSN oligomers but not monomers. Subsequent aggregation assays further show that these compounds also deter or block αSN fibril assembly.https://doi.org/10.1038/s41531-021-00195-6
collection DOAJ
language English
format Article
sources DOAJ
author Anthony R. Braun
Elly E. Liao
Mian Horvath
Prakriti Kalra
Karen Acosta
Malaney C. Young
Noah Nathan Kochen
Chih Hung Lo
Roland Brown
Michael D. Evans
William C. K. Pomerantz
Elizabeth Rhoades
Kelvin Luk
Razvan L. Cornea
David D. Thomas
Jonathan N. Sachs
spellingShingle Anthony R. Braun
Elly E. Liao
Mian Horvath
Prakriti Kalra
Karen Acosta
Malaney C. Young
Noah Nathan Kochen
Chih Hung Lo
Roland Brown
Michael D. Evans
William C. K. Pomerantz
Elizabeth Rhoades
Kelvin Luk
Razvan L. Cornea
David D. Thomas
Jonathan N. Sachs
Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors
npj Parkinson's Disease
author_facet Anthony R. Braun
Elly E. Liao
Mian Horvath
Prakriti Kalra
Karen Acosta
Malaney C. Young
Noah Nathan Kochen
Chih Hung Lo
Roland Brown
Michael D. Evans
William C. K. Pomerantz
Elizabeth Rhoades
Kelvin Luk
Razvan L. Cornea
David D. Thomas
Jonathan N. Sachs
author_sort Anthony R. Braun
title Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors
title_short Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors
title_full Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors
title_fullStr Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors
title_full_unstemmed Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors
title_sort potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved fret biosensors
publisher Nature Publishing Group
series npj Parkinson's Disease
issn 2373-8057
publishDate 2021-06-01
description Abstract We have developed a high-throughput drug discovery platform, measuring fluorescence resonance energy transfer (FRET) with fluorescent alpha-synuclein (αSN) biosensors, to detect spontaneous pre-fibrillar oligomers in living cells. Our two αSN FRET biosensors provide complementary insight into αSN oligomerization and conformation in order to improve the success of drug discovery campaigns for the treatment of Parkinson’s disease. We measure FRET by fluorescence lifetime, rather than traditional fluorescence intensity, providing a structural readout with greater resolution and precision. This facilitates identification of compounds that cause subtle but significant conformational changes in the ensemble of oligomeric states that are easily missed using intensity-based FRET. We screened a 1280-compound small-molecule library and identified 21 compounds that changed the lifetime by >5 SD. Two of these compounds have nanomolar potency in protecting SH-SY5Y cells from αSN-induced death, providing a nearly tenfold improvement over known inhibitors. We tested the efficacy of several compounds in a primary mouse neuron assay of αSN pathology (phosphorylation of mouse αSN pre-formed fibrils) and show rescue of pathology for two of them. These hits were further characterized with biophysical and biochemical assays to explore potential mechanisms of action. In vitro αSN oligomerization, single-molecule FRET, and protein-observed fluorine NMR experiments demonstrate that these compounds modulate αSN oligomers but not monomers. Subsequent aggregation assays further show that these compounds also deter or block αSN fibril assembly.
url https://doi.org/10.1038/s41531-021-00195-6
work_keys_str_mv AT anthonyrbraun potentinhibitorsoftoxicalphasynucleinidentifiedviacellulartimeresolvedfretbiosensors
AT ellyeliao potentinhibitorsoftoxicalphasynucleinidentifiedviacellulartimeresolvedfretbiosensors
AT mianhorvath potentinhibitorsoftoxicalphasynucleinidentifiedviacellulartimeresolvedfretbiosensors
AT prakritikalra potentinhibitorsoftoxicalphasynucleinidentifiedviacellulartimeresolvedfretbiosensors
AT karenacosta potentinhibitorsoftoxicalphasynucleinidentifiedviacellulartimeresolvedfretbiosensors
AT malaneycyoung potentinhibitorsoftoxicalphasynucleinidentifiedviacellulartimeresolvedfretbiosensors
AT noahnathankochen potentinhibitorsoftoxicalphasynucleinidentifiedviacellulartimeresolvedfretbiosensors
AT chihhunglo potentinhibitorsoftoxicalphasynucleinidentifiedviacellulartimeresolvedfretbiosensors
AT rolandbrown potentinhibitorsoftoxicalphasynucleinidentifiedviacellulartimeresolvedfretbiosensors
AT michaeldevans potentinhibitorsoftoxicalphasynucleinidentifiedviacellulartimeresolvedfretbiosensors
AT williamckpomerantz potentinhibitorsoftoxicalphasynucleinidentifiedviacellulartimeresolvedfretbiosensors
AT elizabethrhoades potentinhibitorsoftoxicalphasynucleinidentifiedviacellulartimeresolvedfretbiosensors
AT kelvinluk potentinhibitorsoftoxicalphasynucleinidentifiedviacellulartimeresolvedfretbiosensors
AT razvanlcornea potentinhibitorsoftoxicalphasynucleinidentifiedviacellulartimeresolvedfretbiosensors
AT daviddthomas potentinhibitorsoftoxicalphasynucleinidentifiedviacellulartimeresolvedfretbiosensors
AT jonathannsachs potentinhibitorsoftoxicalphasynucleinidentifiedviacellulartimeresolvedfretbiosensors
_version_ 1721320256165642240